TRCT
ABUS icon

Tower Research Capital (TRC)’s Arbutus Biopharma ABUS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.3K Buy
16,295
+8,288
+104% +$36.2K ﹤0.01% 2431
2025
Q4 		$38.5K Sell
8,007
-4,687
-37% -$21.1K ﹤0.01% 2626
2025
Q3 		$57.6K Sell
12,694
-8,066
-39% -$29.6K ﹤0.01% 2417
2025
Q2 		$64.1K Buy
20,760
+14,275
+220% +$47.4K ﹤0.01% 2753
2025
Q1 		$22.6K Sell
6,485
-6,294
-49% -$21K ﹤0.01% 2841
2024
Q4 		$41.8K Buy
12,779
+1,900
+17% +$6.99K ﹤0.01% 2668
2024
Q3 		$41.9K Sell
10,879
-5,454
-33% -$20.9K ﹤0.01% 2818
2024
Q2 		$50.5K Buy
16,333
+14,474
+779% +$43.4K ﹤0.01% 3094
2024
Q1 		$4.8K Sell
1,859
-4,396
-70% -$11.4K ﹤0.01% 4626
2023
Q4 		$15.6K Sell
6,255
-3,254
-34% -$6.37K ﹤0.01% 3816
2023
Q3 		$19.3K Buy
9,509
+2,397
+34% +$5.03K ﹤0.01% 3411
2023
Q2 		$16.4K Sell
7,112
-2,680
-27% -$6.98K ﹤0.01% 3565
2023
Q1 		$30K Sell
9,792
-5,026
-34% -$14.2K ﹤0.01% 2980
2022
Q4 		$35K Buy
14,818
+4,170
+39% +$9.97K ﹤0.01% 2600
2022
Q3 		$21K Sell
10,648
-5,375
-34% -$12.7K ﹤0.01% 3879
2022
Q2 		$43K Buy
16,023
+5,450
+52% +$13.9K ﹤0.01% 3030
2022
Q1 		$31K Buy
10,573
+5,963
+129% +$18.3K ﹤0.01% 3100
2021
Q4 		$17K Sell
4,610
-1,152
-20% -$4.47K ﹤0.01% 3826
2021
Q3 		$25K Sell
5,762
-2,844
-33% -$9.48K ﹤0.01% 3508
2021
Q2 		$26K Buy
8,606
+4,158
+93% +$12.9K ﹤0.01% 3631
2021
Q1 		$15K Sell
4,448
-130
-3% -$502 ﹤0.01% 4088
2020
Q4 		$16K Buy
4,578
+175
+4% +$613 ﹤0.01% 3994
2020
Q3 		$14K Sell
4,403
-6,941
-61% -$21.1K ﹤0.01% 3954
2020
Q2 		$21K Sell
11,344
-899
-7% -$1.47K ﹤0.01% 3644
2020
Q1 		$12K Buy
12,243
+12,143
+12,143% +$32.8K ﹤0.01% 1927
2019
Q4 		$0 Sell
100
-38,689
-100% -$62.6K ﹤0.01% 3438
2019
Q3 		$59K Buy
38,789
+34,005
+711% +$58.6K ﹤0.01% 1669
2019
Q2 		$10K Sell
4,784
-2,861
-37% -$7.32K ﹤0.01% 2540
2019
Q1 		$28K Sell
7,645
-2,564
-25% -$9.84K ﹤0.01% 2079
2018
Q4 		$39K Buy
10,209
+8,647
+554% +$42.6K ﹤0.01% 1446
2018
Q3 		$15K Buy
1,562
+850
+119% +$8.44K ﹤0.01% 2511
2018
Q2 		$5K Sell
712
-1,836
-72% -$10.9K ﹤0.01% 3045
2018
Q1 		$13K Buy
+2,548
New +$13.5K ﹤0.01% 2349
2017
Q4 		– Sell
-8,283
Closed -$51K – 3447
2017
Q3 		$51K Sell
8,283
-1,943
-19% -$8.31K ﹤0.01% 1947
2017
Q2 		$37K Buy
10,226
+5,377
+111% +$18.5K ﹤0.01% 897
2017
Q1 		$16K Sell
4,849
-3,803
-44% -$10.6K ﹤0.01% 1420
2016
Q4 		$21K Buy
8,652
+7,180
+488% +$20.9K ﹤0.01% 2076
2016
Q3 		$5K Sell
1,472
-810
-35% -$3.17K ﹤0.01% 2516
2016
Q2 		$8K Sell
2,282
-3,913
-63% -$16.6K ﹤0.01% 2998
2016
Q1 		$25K Sell
6,195
-1,471
-19% -$5.25K ﹤0.01% 1179
2015
Q4 		$35K Buy
7,666
+2,366
+45% +$13K 0.01% 758
2015
Q3 		$32K Hold
5,300
– – ﹤0.01% 1331
2015
Q2 		$63K Sell
5,300
-12
-0.2% -$183 0.01% 1183
2015
Q1 		$93K Buy
5,312
+4,500
+554% +$92.2K 0.01% 957
2014
Q4 		$12K Buy
812
+621
+325% +$10.7K ﹤0.01% 1965
2014
Q3 		$4K Sell
191
-546
-74% -$8.91K ﹤0.01% 3395
2014
Q2 		$10K Sell
737
-95
-11% -$1.35K ﹤0.01% 2337
2014
Q1 		$18K Sell
832
-3,084
-79% -$55.4K ﹤0.01% 1981
2013
Q4 		$31K Buy
3,916
+2,631
+205% +$21.9K 0.01% 1839
2013
Q3 		$9K Buy
+1,285
New +$7.08K ﹤0.01% 3258

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Tower Research Capital (TRC)'s ABUS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Arbutus Biopharma (ABUS) stake by 104% in Q1 2026, buying an estimated $36.2K and bringing the position to 16,295 shares worth $73.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

Tower Research Capital (TRC) first reported a position in ABUS in Q3 2013 and has held it in 50 quarters since. The position peaked at $93K in Q1 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Tower Research Capital (TRC) held 16,295 shares of Arbutus Biopharma worth $73.3K as of Q1 2026.
  • Tower Research Capital (TRC) bought 8,288 Arbutus Biopharma shares in Q1 2026, an estimated $36.2K.
  • Arbutus Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2431 holding.
  • Tower Research Capital (TRC) first reported a position in Arbutus Biopharma in Q3 2013 and has held it in 50 quarters since.
  • Tower Research Capital (TRC)'s Arbutus Biopharma position peaked at $93K in Q1 2015.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.